Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
US pharma major Bristol-Myers Squibb today reported results for the fourth quarter and full year of 2018 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (apixaban) and a robust operating performance across the portfolio. 24 January 2019
Circassia Pharmaceuticals has entered into a definitive agreement to acquire the exclusive commercialization rights from AIT Therapeutics to its ventilator compatible nitric oxide product, AirNOvent, a treatment for persistent pulmonary hypertension (PPHN) of the newborn, in the USA and China. 24 January 2019
More than half of consumers lack confidence in their ability to properly take new medications as directed, according to a survey released today by DrFirst, a leading US provider of e-prescribing and patient medication management solutions. 23 January 2019
In a unanimous opinion, the US Supreme Court solidified that inventors lose patent protection for inventions that they had sold or offered to sell more than a year before submitting the patent application - even if those sales were confidential and did not publicize the invention’s details. 23 January 2019
Shares in Canadian immunology specialist Aurinia Pharmaceuticals have fallen over 8% since the firm announced mixed results for its dry eye therapy VOS (voclosporin), in a Phase II head-to-head study against Restasis (cyclosporine). 23 January 2019
Progress and growth of the Russian pharmaceutical industry were the subject of press conference yesterday, under the theme: “Initiatives to support Russian manufacturers, myths and reality.” 23 January 2019
New draft guidance has recommended international standards for the use of nonclinical safety studies to support the development of pediatric medicines. 23 January 2019
Ferring Pharmaceuticals says it has entered a five-year extension of its agreement with the Karolinska Institutet to explore the potential of the human microbiome in reproductive medicine and women’s health and gastroenterology. 23 January 2019
Nearly £60 million ($77 million) has been given to researchers from across North America, Europe and Israel by the world’s leading cancer research charity. 23 January 2019
Shares in Johnson & Johnson slumped by 2% in Tuesday morning’s trading after the US healthcare conglomerate announced its 2018 financial results and outlook for 2019. 22 January 2019
Japanese drugmaker Takeda is said to be considering a sale of certain therapies in emerging markets, with the aim of reducing its debt burden in the wake of its $62 billion purchase of rare disease specialist Shire. 22 January 2019
Swiss drugmaker Vifor Pharma has clarified what it calls a ‘programming error’ in the original analysis by the investigators in the PIVOTAL trial. 22 January 2019
Privately-held Spanish drugmaker Esteve has announced the RIBOPAIN project, which aims to identify new therapeutic solutions for pain and to develop more effective drugs in collaboration with the Neuropharmacology Group-Neurophar at Pompeu Fabra University (UPF). 22 January 2019
Japanese companies Meiji Seika Pharma and Toray Industries have signed a licensing agreement for the development and commercialization of the antipruritic drug, TRK-820 (nalfurafine hydrochloride), in Thailand and Indonesia. 21 January 2019
The UK’s reimbursement agency has reversed a conditional decision not to recommend funding for the breast cancer therapy Verzenio (abemaciclib) through the country’s national healthcare provider. 21 January 2019
Russian and foreign drugmakers operating in the local market, will be obliged to reduce prices of drugs, which have a status of vital and essential in Russia if prices for these drugs have declined in the country of origin or in a number of countries abroad, according to the latest initiative of the Russian government. 21 January 2019
Sir Philip Hampton, who since 2015 has been the non-executive chairman of GlaxoSmithKline, will step down from the role with the UK drugmaker. 21 January 2019